International Stem Cell Corporation (ISCO)
USD 0.12
(20.0%)
USD 0.12
(20.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -131 Thousand USD | 71.89% |
| 2022 | -466 Thousand USD | 55.19% |
| 2021 | -1.04 Million USD | 63.34% |
| 2020 | -2.83 Million USD | 34.69% |
| 2019 | -4.34 Million USD | -103.85% |
| 2018 | -2.13 Million USD | 64.89% |
| 2017 | -6.06 Million USD | -462.47% |
| 2016 | -1.07 Million USD | 59.05% |
| 2015 | -2.63 Million USD | 78.88% |
| 2014 | -12.47 Million USD | -19.08% |
| 2013 | -10.47 Million USD | -6.57% |
| 2012 | -9.83 Million USD | -7.22% |
| 2011 | -9.17 Million USD | 7.39% |
| 2010 | -9.9 Million USD | -27.4% |
| 2009 | -7.77 Million USD | -18.28% |
| 2008 | -6.57 Million USD | -8.22% |
| 2007 | -6.07 Million USD | 7.78% |
| 2006 | -6.58 Million USD | -79262.67% |
| 2005 | -8296.00 USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -214 Thousand USD | 53.28% |
| 2024 Q2 | 62 Thousand USD | 155.61% |
| 2023 Q4 | -458 Thousand USD | -249.62% |
| 2023 Q1 | -106 Thousand USD | -606.67% |
| 2023 Q2 | 492 Thousand USD | 564.15% |
| 2023 FY | -131 Thousand USD | 71.89% |
| 2023 Q3 | -131 Thousand USD | -126.63% |
| 2022 Q2 | -35 Thousand USD | 18.6% |
| 2022 FY | -466 Thousand USD | 55.19% |
| 2022 Q4 | -15 Thousand USD | 95.63% |
| 2022 Q3 | -343 Thousand USD | -880.0% |
| 2022 Q1 | -43 Thousand USD | 87.75% |
| 2021 Q2 | 216 Thousand USD | 136.06% |
| 2021 Q3 | -165 Thousand USD | -176.39% |
| 2021 FY | -1.04 Million USD | 63.34% |
| 2021 Q1 | -599 Thousand USD | 16.92% |
| 2021 Q4 | -351 Thousand USD | -112.73% |
| 2020 Q2 | -1.08 Million USD | -191.15% |
| 2020 FY | -2.83 Million USD | 34.69% |
| 2020 Q3 | -544 Thousand USD | 49.91% |
| 2020 Q4 | -721 Thousand USD | -32.54% |
| 2020 Q1 | -373 Thousand USD | 86.25% |
| 2019 Q1 | -906 Thousand USD | 11.87% |
| 2019 Q4 | -2.71 Million USD | -90533.33% |
| 2019 FY | -4.34 Million USD | -103.85% |
| 2019 Q2 | -648 Thousand USD | 28.48% |
| 2019 Q3 | 3000.00 USD | 100.46% |
| 2018 Q2 | -393 Thousand USD | 52.65% |
| 2018 Q4 | -1.02 Million USD | -949.59% |
| 2018 FY | -2.13 Million USD | 64.89% |
| 2018 Q1 | -830 Thousand USD | 40.24% |
| 2018 Q3 | 121 Thousand USD | 130.79% |
| 2017 Q3 | -2.16 Million USD | -480.99% |
| 2017 FY | -6.06 Million USD | -462.47% |
| 2017 Q1 | -3.08 Million USD | -242.71% |
| 2017 Q4 | -1.38 Million USD | 35.81% |
| 2017 Q2 | 568 Thousand USD | 118.42% |
| 2016 FY | -1.07 Million USD | 59.05% |
| 2016 Q4 | 2.16 Million USD | 421.98% |
| 2016 Q3 | 414 Thousand USD | -96.21% |
| 2016 Q2 | 10.91 Million USD | 174.93% |
| 2016 Q1 | -14.57 Million USD | -851.24% |
| 2015 Q3 | -539 Thousand USD | -174.55% |
| 2015 Q2 | 723 Thousand USD | 156.18% |
| 2015 FY | -2.63 Million USD | 78.88% |
| 2015 Q1 | -1.28 Million USD | 72.02% |
| 2015 Q4 | -1.53 Million USD | -184.23% |
| 2014 FY | -12.47 Million USD | -19.08% |
| 2014 Q4 | -4.59 Million USD | -126.11% |
| 2014 Q1 | -1.43 Million USD | 48.14% |
| 2014 Q2 | -4.41 Million USD | -207.32% |
| 2014 Q3 | -2.03 Million USD | 53.88% |
| 2013 Q4 | -2.76 Million USD | 27.17% |
| 2013 FY | -10.47 Million USD | -6.57% |
| 2013 Q1 | -1.71 Million USD | 34.13% |
| 2013 Q2 | -2.2 Million USD | -28.5% |
| 2013 Q3 | -3.79 Million USD | -72.68% |
| 2012 Q4 | -2.59 Million USD | -24.89% |
| 2012 FY | -9.83 Million USD | -7.22% |
| 2012 Q1 | -2.67 Million USD | -2.04% |
| 2012 Q2 | -2.47 Million USD | 7.47% |
| 2012 Q3 | -2.08 Million USD | 15.99% |
| 2011 Q3 | -2.56 Million USD | -7.32% |
| 2011 Q2 | -2.38 Million USD | -65.97% |
| 2011 FY | -9.17 Million USD | 7.39% |
| 2011 Q1 | -1.43 Million USD | 41.49% |
| 2011 Q4 | -2.62 Million USD | -2.32% |
| 2010 Q2 | 2.41 Million USD | 133.96% |
| 2010 Q1 | -7.12 Million USD | -2339.92% |
| 2010 FY | -9.9 Million USD | -27.4% |
| 2010 Q3 | -2.93 Million USD | -221.44% |
| 2010 Q4 | -2.46 Million USD | 16.26% |
| 2009 Q1 | -1.95 Million USD | -11.27% |
| 2009 Q4 | -292.01 Thousand USD | 82.38% |
| 2009 Q3 | -1.65 Million USD | 60.79% |
| 2009 Q2 | -4.22 Million USD | -115.97% |
| 2009 FY | -7.77 Million USD | -18.28% |
| 2008 Q4 | -1.75 Million USD | -25.44% |
| 2008 Q2 | -1.79 Million USD | -11.19% |
| 2008 Q1 | -1.61 Million USD | -0.62% |
| 2008 FY | -6.57 Million USD | -8.22% |
| 2008 Q3 | -1.4 Million USD | 21.95% |
| 2007 FY | -6.07 Million USD | 7.78% |
| 2007 Q4 | -1.6 Million USD | -10.31% |
| 2007 Q1 | -1.69 Million USD | 74.19% |
| 2007 Q2 | -1.7 Million USD | -0.44% |
| 2007 Q3 | -1.45 Million USD | 14.44% |
| 2006 Q2 | -1122.00 USD | 91.19% |
| 2006 FY | -6.58 Million USD | -79262.67% |
| 2006 Q1 | -12.74 Thousand USD | 0.0% |
| 2006 Q4 | -6.55 Million USD | -63046.65% |
| 2006 Q3 | -10.38 Thousand USD | -825.85% |
| 2005 FY | -8296.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 90.19% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 98.124% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 100.247% |
| Nascent Biotech, Inc. | -2.08 Million USD | 93.725% |
| Rebus Holdings, Inc. | -1.02 Million USD | 87.157% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 100.201% |
| Qrons Inc. | -789.34 Thousand USD | 83.404% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 79.285% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 99.791% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 68.47% |
| Skye Bioscience, Inc. | -37.64 Million USD | 99.652% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 99.825% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 98.008% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 52.085% |
| SQZ Biotechnologies Company | -79.46 Million USD | 99.835% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 95.471% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 92.804% |
| Mesoblast Limited | -87.95 Million USD | 99.851% |
| Marizyme, Inc. | -65.34 Million USD | 99.8% |
| Genus plc | 7.9 Million USD | 101.658% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 98.797% |
| Pharming Group N.V. | -10.54 Million USD | 98.758% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 93.963% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 96.469% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 98.519% |
| ContraFect Corporation | -65.15 Million USD | 99.799% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 97.319% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 92.417% |
| IMV Inc. | -36.48 Million USD | 99.641% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 98.375% |
| MultiCell Technologies, Inc. | -380.07 USD | -34367.335% |
| ONE Bio Corp. | 8.67 Million USD | 101.51% |
| Accustem Sciences Inc. | -3.74 Million USD | 96.503% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 99.747% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 89.662% |
| Q BioMed Inc. | -2.05 Million USD | 93.616% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 96.491% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 94.498% |
| Biomind Labs Inc. | -1.21 Million USD | 89.212% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 99.781% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 95.777% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 98.342% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 93.279% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | -774.733% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 99.175% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 97.748% |
| GB Sciences, Inc. | -1.36 Million USD | 90.38% |
| Alpha Cognition Inc. | -13.77 Million USD | 99.049% |
| HST Global, Inc. | -146.21 Thousand USD | 10.403% |
| CSL Limited | 2.64 Billion USD | 100.005% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 92.535% |
| Halberd Corporation | -79.67 Thousand USD | -64.416% |
| Enzolytics Inc. | -2.17 Million USD | 93.982% |
| Agentix Corp. | -1.37 Million USD | 90.467% |
| Resverlogix Corp. | -3.61 Million USD | 96.371% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 95.869% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -295.05 Million USD | 99.956% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | 233.673% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 101.892% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 96.703% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 95.671% |
| AVAX Technologies, Inc. | -6.41 Million USD | 97.957% |
| Zenith Capital Corp. | -10.59 Million USD | 98.764% |
| Genscript Biotech Corporation | -95.47 Million USD | 99.863% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | -463.635% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 96.84% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | -116.742% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 93.467% |
| Kadimastem Ltd | -3.3 Million USD | 96.039% |
| Helix BioMedix, Inc. | -1.05 Million USD | 87.595% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 96.57% |
| BioStem Technologies, Inc. | -8.48 Million USD | 98.456% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 70.32% |
| LadRx Corporation | 400.44 Thousand USD | 132.714% |
| Cell Source, Inc. | -5.32 Million USD | 97.538% |
| Regen BioPharma, Inc. | 1.02 Million USD | 112.799% |
| Regen BioPharma, Inc. | 1.02 Million USD | 112.799% |
| NovAccess Global Inc. | -4.76 Million USD | 97.253% |
| Affymax, Inc. | -14.42 Million USD | 99.092% |
| Itoco Inc. | -1.86 Million USD | 92.991% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 97.051% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 92.151% |
| Mobile Lads Corp. | -2.26 Million USD | 94.212% |
| CytoDyn Inc. | -49.84 Million USD | 99.737% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | -65.754% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 42.576% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 86.086% |
| SYBLEU INC | -180.3 Thousand USD | 27.345% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 91.877% |
| Bioxytran, Inc. | -4.28 Million USD | 96.939% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | -141.377% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 94.823% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 99.727% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 93.803% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 83.224% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 95.865% |
| Neutra Corp. | -233.46 Thousand USD | 43.889% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 99.354% |
| PureTech Health plc | -65.69 Million USD | 99.801% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 99.384% |
| IXICO plc | -1.17 Million USD | 88.879% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 98.68% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 99.771% |
| CSL Limited | 2.64 Billion USD | 100.005% |
| Cellectis S.A. | -103.17 Million USD | 99.873% |